Abstract
Reducing the aggregation of proteins is of utmost interest to the pharmaceutical industry. Aggregated proteins are often less active and can cause severe immune reactions in the patient upon administration. At the same time the biopharmaceutical market is pushing for high concentration formulations and products that do not require refrigerated storage conditions. For a given protein, the liquid formulation developer’s toolbox is limited to achieve these goals: pH, ionic strength and concentration of a very limited number of excipients are the only solution parameters to be varied. In this work, we present a structure-based approach to discover new molecules that successfully reduce the aggregation of proteins and apply it to the model protein Interferon-alpha-2a.
Dokumententyp: | Zeitschriftenartikel |
---|---|
EU Funded Grant Agreement Number: | 675074 |
EU-Projekte: | Horizon 2020 > Marie Skłodowska Curie Actions > Marie Skłodowska-Curie Innovative Training Networks > 675074: PIPPI - Protein-excipient Interactions and Protein-Protein Interactions in formulation |
Keywords: | Interferon-alpha-2a; Virtual Screen; Excipient; Protein Aggregation; Protein Formulation; Drug Discovery |
Fakultät: | Chemie und Pharmazie > Department für Pharmazie - Zentrum für Pharmaforschung
Chemie und Pharmazie > Department Chemie |
Themengebiete: | 500 Naturwissenschaften und Mathematik > 540 Chemie |
URN: | urn:nbn:de:bvb:19-epub-69089-1 |
Sprache: | Englisch |
Dokumenten ID: | 69089 |
Datum der Veröffentlichung auf Open Access LMU: | 26. Sep. 2019 05:15 |
Letzte Änderungen: | 04. Nov. 2020 13:51 |